Literature DB >> 2651920

Antimalarial action of nitrobenzylthioinosine in combination with purine nucleoside antimetabolites.

A M Gero1, H V Scott, W J O'Sullivan, R I Christopherson.   

Abstract

The infection of human erythrocytes by two strains of the human malarial parasite, Plasmodium falciparum (FCQ-27 or the multi-drug-resistant strain K-1), markedly changed the transport characteristics of the nucleosides, adenosine and tubercidin, compared to uninfected erythrocytes. A component of the transport of these nucleosides was insensitive to the classical mammalian nucleoside transport inhibitor nitrobenzylthioinosine (NBMPR). In vitro studies with tubercidin demonstrated ID50 values of 0.43 and 0.51 microM for FCQ-27 and K-1, respectively. In addition, the nucleoside transport inhibitors NBMPR, nitrobenzylthioguanosine (NBTGR), dilazep and dipyridamole also independently exhibited antimalarial activity in vitro. The combination of tubercidin and NBMPR or NBTGR in vitro demonstrated synergistic activity, whilst tubercidin together with dilazep or dipyridamole showed subadditive activity. Analysis by HPLC indicated that NBMPR could permeate the infected cell membrane and provided evidence for the catabolism of NBMPR in vitro, with subsequent alteration of the purine pool in the infected erythrocyte. These observations further indicated the possibility of the utilization of cytotoxic nucleosides against P. falciparum infection in conjunction with a nucleoside transport inhibitor to protect the host tissue.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2651920     DOI: 10.1016/0166-6851(89)90023-6

Source DB:  PubMed          Journal:  Mol Biochem Parasitol        ISSN: 0166-6851            Impact factor:   1.759


  8 in total

1.  Parasite-induced processes for adenosine permeation in mouse erythrocytes infected with the malarial parasite Plasmodium yoelii.

Authors:  W P Gati; A N Lin; T I Wang; J D Young; A R Paterson
Journal:  Biochem J       Date:  1990-11-15       Impact factor: 3.857

Review 2.  Pyrimidine metabolism in schistosomes: A comparison with other parasites and the search for potential chemotherapeutic targets.

Authors:  Mahmoud H El Kouni
Journal:  Comp Biochem Physiol B Biochem Mol Biol       Date:  2017-07-21       Impact factor: 2.231

3.  Purine salvage and metabolism in Babesia bovis.

Authors:  C Matias; S E Nott; A S Bagnara; W J O'Sullivan; A M Gero
Journal:  Parasitol Res       Date:  1990       Impact factor: 2.289

Review 4.  Purine import into malaria parasites as a target for antimalarial drug development.

Authors:  I J Frame; Roman Deniskin; Avish Arora; Myles H Akabas
Journal:  Ann N Y Acad Sci       Date:  2014-11-25       Impact factor: 5.691

5.  Malaria parasite type 4 equilibrative nucleoside transporters (ENT4) are purine transporters with distinct substrate specificity.

Authors:  I J Frame; Emilio F Merino; Vern L Schramm; María B Cassera; Myles H Akabas
Journal:  Biochem J       Date:  2012-09-01       Impact factor: 3.857

6.  PfPDE1, a novel cGMP-specific phosphodiesterase from the human malaria parasite Plasmodium falciparum.

Authors:  Keizo Yuasa; Fumika Mi-Ichi; Tamaki Kobayashi; Masaya Yamanouchi; Jun Kotera; Kiyoshi Kita; Kenji Omori
Journal:  Biochem J       Date:  2005-11-15       Impact factor: 3.857

7.  Hot shot induction and reperfusion with a specific blocker of the es-ENT1 nucleoside transporter before and after hypothermic cardioplegia abolishes myocardial stunning in acutely ischemic hearts despite metabolic derangement: hot shot drug delivery before hypothermic cardioplegia.

Authors:  Anwar Saad Abd-Elfattah; Gert E Tuchy; Michael E Jessen; David R Salter; Jacques P Goldstein; Louis A Brunsting; Andrew S Wechsler
Journal:  J Thorac Cardiovasc Surg       Date:  2013-02-17       Impact factor: 5.209

8.  Uptake of purines in Plasmodium falciparum-infected human erythrocytes is mostly mediated by the human equilibrative nucleoside transporter and the human facilitative nucleobase transporter.

Authors:  Neils B Quashie; Lisa C Ranford-Cartwright; Harry P de Koning
Journal:  Malar J       Date:  2010-01-29       Impact factor: 2.979

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.